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To elucidate the mechanisms of antischistosoma resistance, drug-resistant Schistosoma mansoni laboratory iso-
lates are essential. We developed a new method for inducing resistance to praziquantel (PZQ) using successive drug 
treatments of Biomphalaria glabrata snails infected with S. mansoni. Infected B. glabrata were treated three times 
with 100 mg/kg PZQ for five consecutive days with a one-week interval between them. After the treatment, the cer-
cariae (LE-PZQ) produced from these snails and the LE strains (susceptible) were used to infect mice. Forty-five 
days after infection, mice were treated with 200, 400 or 800 mg/kg PZQ. Thirty days post-treatment, we observed 
that the mean number of worms recovered by perfusion was significantly higher in the group of mice infected with the 
LE-PZQ isolate treated with 200 and 400 mg/kg in comparison to the LE strain with the same treatment. Moreover, 
there was a significant difference between the ED50 (effective dose required to kill 50% of the worms) of the LE-PZQ 
isolate (362 mg/kg) and the LE strain (68 mg/kg). In the in vitro assays, the worms of the LE-PZQ isolate were also 
less susceptible to PZQ. Thus, the use of infected snails as an experimental model for development of resistance to 
S. mansoni is effective, fast, simple and cheap.
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The current strategy for schistosomiasis control is 
based on large-scale treatments of populations aimed 
at reducing disease morbidity (WHO 2002). Currently, 
praziquantel (PZQ) is the drug of choice (Utzinger & 
Keiser 2004, Fenwick & Webster 2006), with the main ad-
vantages of its use being oral administration, single dose, 
low toxicity and low cost (Fenwick et al. 2003, Utzinger 
& Keiser 2004). Despite the advantages of PZQ, there is 
concern about the development of Schistosoma mansoni 
resistance to PZQ, both under laboratory and field condi-
tions (Abdul-Ghani et al. 2009). In the laboratory, induc-
tion of resistance is based on the treatment of mice in-
fected with S. mansoni, initially using sub-curative doses 
of PZQ. Afterwards, the dosage is increased for at least 
seven passages in mice/snails to complete the life cycle of 
the parasite (Ismail et al. 1994, Fallon et al. 1995). 
The complete mechanism of action of PZQ is still 
unclear (Doenhoff et al. 2008). Obtaining resistant 
strains is important for the evaluation of such mecha-
nisms as well as for the development of alternative drugs 
for schistosomiasis treatment and control. Studies show 
that PZQ is effective not only in adult worms, but also 
in the intramolluscan phase of the parasite (Coelho et al. 
1988, Mattos et al. 2006, 2007). We report a novel meth-
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od for the induction (or selection) of S. mansoni worms 
resistant to PZQ using successive treatments of infected 
Biomphalaria glabrata snails.
SUBJECTS, MATERIALS AND METHODS
Parasites and hosts - The S. mansoni (LE strain) life 
cycle was maintained using B. glabrata (Barreiro de 
Cima strain) snails as intermediate hosts and Swiss mice 
as definitive hosts, according to Pellegrino and Katz 
(1968) and Souza et al. (1995).
Perfusion of adult worms from infected mice - Two 
methods were used. The methodology described by 
Pellegrino and Siqueira (1956) used a needle attached 
to a Brewer’s automatic pipetter to inject saline solution 
under pressure into the descendent aorta. Afterwards, 
saline was injected into the hepatic hilum of mice af-
ter sectioning the portal vein, allowing the perfusion of 
the portal system and mesenteric veins. Worms were 
recovered and counted. To recover the worms using the 
methodology described by Smithers and Terry (1965) 
the portal vein of the mice was sectioned and the cul-
ture medium was gently injected into the base of the 
left ventricle of the infected mice’s hearts. It is not pos-
sible to recover all the worms using this methodology 
with a lower pressure injection, but the integrity of the 
parasite’s tegument is preserved. Therefore, this meth-
odology is ideal for the recovery of worms when the 
goal is to cultivate or evaluate other parameters such as 
tegumental integrity and/or excretory activity.
Induction of resistance to PZQ in the intramolluscan 
phase - Two-hundred B. glabrata were individually in-
fected with 10 S. mansoni miracidia (Mattos et al. 2007). 
Thirty days post-infection the snails were exposed to ar-
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tificial light for 1 h to verify the shedding of cercariae 
(Souza et al. 1995). The snails shedding cercariae were 
divided into two groups (infected snail or infected snails 
treated with PZQ). The snails were individually weighed 
using an analytical balance and the snails’ mean weight 
was used to calculate the drug dosage to be adminis-
tered. The snails were individually treated with 100 mg/
kg PZQ for five consecutive days. This treatment was 
repeated three times, with a one-week interval between 
the treatments. PZQ was added to the 100 mg of food 
(mouse chow; Nuvital) daily allowance. The ration was 
reconstituted in water until it became pasty and then 
PZQ was added. The untreated snails received the same 
amount of food daily without PZQ (Mattos et al. 2007). 
The daily amount of food given each day was totally in-
gested by each snail, suggesting that the snails received 
all of the drugs offered in ration. The snails were kept in 
plastic glasses containing 200 mL dechlorinated water 
which was changed daily. At the end of the treatments, 
the snails were exposed each week to artificial light until 
cercarial shedding occurred in sufficient number for the 
infection of mice, which occurred in about 60 days.
Evaluation of PZQ pressure on parasites at the in-
tramolluscan phase - Treatment with PZQ: mice were 
infected with 25 S. mansoni cercariae by the subcuta-
neous route (Pellegrino & Katz 1968). Eighty-four mice 
were infected with cercariae derived from snails treated 
with PZQ, called the LE-PZQ isolate and another 84 
mice infected with cercariae developed from untreated 
snails, called the LE strain. Forty-five days after infec-
tion, mice were divided into groups (12 mice in each 
group). Two experiments were performed: in the first 
the mice were treated with 200 or 400 mg/kg PZQ; in 
the second experiment, mice were treated with 200, 400 
or 800 mg/kg. In both experiments a single oral dose 
was used. An untreated group was included as a control. 
Thirty-three days after treatment, mice were submitted 
to perfusion for evaluation of worm burden reduction 
(Pellegrino & Siqueira 1956). The percentage of reduc-
tion for each group and each experiment was calculated 
according to the following formula: 
% reduction = 
(mean of worms in control group - mean of worms in 
control treated)  x 100
(mean of worms in control group)
The mean of worm reduction related to the experi-
ments 1 and 2 for each PZQ dose was calculated and 
then the effective dose required to kill 50% of the worms 
(ED50) was estimated. Data were analyzed using Minitab 
13 and GraphPad Prism 4 computer software using the 
sigmoidal curve, with 5% significance.
In vitro observation of worms treated with PZQ - 
Mice infected with 100 cercariae derived from S. man-
soni LE or LE-PZQ isolates were treated with 400 mg/
kg PZQ 45 days post-infection. Two hours later, mice 
were perfused using Roswell Park Memorial Institute 
medium (RPMI) 1640 medium with 2% heparin (Smith-
ers & Terry 1965). Four pairs of worms originating from 
LE or LE-PZQ isolates were put in 6-well culture plates 
containing 4 mL RPMI 1640 supplemented with 5% foe-
tal bovine serum and 100 µg/mL of penicillin and strep-
tomycin, and were cultivated in a 5% CO2 incubator for 
eight days at a temperature of 37ºC. The worms derived 
from LE or LE-PZQ isolates and recovered from un-
treated mice were also cultivated and used as a control.
RESULTS
Evaluation of PZQ pressure in parasites at the intra-
molluscan phase - Treatment with PZQ - in this experi-
ment, two doses of PZQ (400 or 800 mg/kg) were tested 
on mice infected with LE and LE-PZQ isolates. A sta-
tistically significant difference (p < 0.03) was observed 
between the mean number of worms recovered from LE-
PZQ (1.9) and the mean from the LE strain (0.42) when 
both were exposed to 400 mg/kg PZQ. Moreover, the 
percentage reduction of worms from the LE-PZQ (43.5%) 
isolate was lower than that found for worms from the 
LE strain (85.6%), suggesting that the LE-PZQ isolate 
showed a reduction of susceptibility to drug action. When 
the higher dose of 800 mg/kg was used, no significant dif-
ference could be observed between the isolates (Table I).
In the second experiment, three doses of PZQ (200, 
400 or 800 mg/kg) were used. The mean number of worms 
recovered from the LE-PZQ isolate treated with 200 mg/
kg (mean of 9.7) and treated with 400 mg/kg (mean of 
5.1) was significantly lower (p < 0.002 and p < 0.01, re-
spectively) than the mean of worms recovered from the 
groups infected with cercariae derived from the LE strain 
and treated with the same doses (mean of 3.0 and 0.6, 
respectively). Moreover, the percentage in reduction of 
worms was as follows: LE-PZQ treated with 200 mg/kg, 
8.8%, with 400 mg/kg, 52.3%, LE treated with 200 mg/
kg, 71.7%, and with 400 mg/kg, 94.3%. No statistically 
significant difference between the isolates could be de-
tected when they were submitted at the dose of 800 mg/kg 
(Table I), corroborating our previous results.
The mean worm reduction in experiments 1 and 2 
was calculated for each PZQ dose (200, 400 or 800 mg/
kg) (Fig. 1, Table II). Based on these means, the ED50 val-
ues obtained were 68 mg/kg and 362 mg/kg for the LE 
and LE-PZQ isolates, respectively, with these values be-
ing significantly different (p < 0.01) (Table II). The ED50 
for the LE-PZQ isolate was 5.3 times higher than that for 
the LE strain. These results show that there is a reduction 
in S. mansoni susceptibility to PZQ when the parasite is 
submitted to PZQ treatment at the intramolluscan phase.
In vitro observation of worms recovered from mice 
treated with PZQ - It was observed that the parasites of 
the LE strain derived from mice treated with 400 mg/kg 
PZQ were more contracted (Fig. 2A) than the parasites 
of LE-PZQ isolate submitted to the same PZQ dose (Fig. 
2B). Additionally, more than 300 eggs were found in the 
cultured LE-PZQ isolate recovered from mice treated 
with 400 mg/kg. Furthermore, eggs in all stages were 
observed after eight days (Fig. 2D). In contrast, the worm 
culture of the LE strain had a smaller number of dead 
eggs (± 30 from total number of cultured worms) (Fig. 
2C). The untreated LE and LE-PZQ isolates showed a 
similar number of eggs from the first stage to the mature 
stage (Fig. 2E, F). These results suggest that LE-PZQ 
isolates have reduced susceptibility to the drug.
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TABLE I
Details of two experiments performed to estimate the percentage reduction of worm burden in mice infected with Schistosoma 
mansoni LE strain (control) and LE-praziquantel (PZQ) and treated with PZQ
Isolate/experimenta PZQ dose (mg/kg) Mean number of worms ± SD Worm reduction (%)
LE/1 400, 800 0.42 ± 0.79, 0.42 ± 1.2 85.6, 85.6
LE-PZQ/1 400, 800 1.9 ± 1.4b, 0.42 ± 0.8 43.5, 87.6
LE/2 200, 400, 800 3.0 ± 2.7, 0.6 ± 1.2, 1.0 ± 1.1 71.7, 94.3, 90.5
LE-PZQ/2 200, 400, 800 9.7 ± 5.8c, 5.1 ± 4.0d, 1.16 ± 1.5 8.8, 52.3, 89.2
a: mean number of worms ± standard deviation (SD) (experiment 1: LE control: 2.92 ± 2.93, LE-PZQ control: 3.4 ± 3.1; experi-
ment 2: LE control: 10.6 ± 6.0, LE-PZQ control: 10.7 ± 6.4); b: statistical difference between LE-PZQ/1400 mg/kg and LE-PZQ/1 
400 mg/kg at p < 0.01; c: statistical difference between LE-PZQ/2200 mg/kg and LE-PZQ/2 200 mg/kg at p < 0.003; d: statistical 
difference between LE-PZQ/2400 mg/kg and LE-PZQ/2 400 mg/kg at p < 0.01.
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Fig. 1: computer-adjusted praziquantel (PZQ) dose-response curves 
for PZQ-susceptible (LE) and that isolate submitted to intramolluscan 
treatment with PZQ (LE-PZQ) of Schistosoma mansoni. The curves 
were fitted to the pooled results from two experiments on each isolate 
listed in Table II using GraphPad Prism 4 computer software.
TABLE II
Results of experiments performed to estimate the effective 
dose required to kill 50% of the worms (ED50) for the  
susceptible Schistosoma mansoni strain (LE) and that  
submitted to treatments with praziquantel (PZQ) at the  
intramolluscan phase (LE-PZQ)
Isolate/PZQ dose
Mean worm 
reduction
% ± SD
ED50 
mg/kg
95%
confidence 
limits
LE 200 mg/kg 71.1 68 -
LE 400 mg/kg 89.9 ± 6.1a - 38.49-121.1
LE 800 mg/kg 88.1 ± 3.5a - -
LE-PZQ 200 mg/kg 8.8 362b -
LE-PZQ 400 mg/kg 47.9 ± 6.2a - 125.7/1.044
LE-PZQ 800 mg/kg 88.4 ± 1.3a - -
a: related to experiments 1 and 2; b: statistical difference be-
tween LE and LE-PZQ ED50. LE-PZQ ED50 is 5.3 times higher 
than LE ED50. P < 0.01; SD: standard deviation.
DISCUSSION
According to Roos et al. (1993) and Liang et al. 
(2003), the process of drug pressure for selection of re-
sistance can be carried out in the laboratory. This is im-
portant since resistant parasites may help elucidate the 
mechanism of the drugs.
The PZQ effective against only adult worms and 
another drugs effective against adult and immature S. 
mansoni worms in the vertebrate host are also effective 
at the intramolluscan stage of the parasite, leading to 
interruption of shedding of cercariae (Warren & Weis-
berger 1966, Warren 1967, Coles 1979, Touassem & 
Combes 1986, Coles & Bruce 1987, Yi & Combes 1987, 
Coelho et al. 1988, Riley & Chappell 1990, Mattos et al. 
2006, 2007).
Mattos et al. (2007) tested different doses and sched-
ules of PZQ in infected B. glabrata and observed that a 
treatment of 1,000 mg/kg PZQ significantly interrupted 
almost 90% of the cercarial shedding until approxi-
mately 30 days after the end of treatment, whereas treat-
ments with other drug formulations (500 mg/kg PZQ and 
250 mg/kg oxamniquine in association) eliminated the 
parasite from the snails. Thus, the dose of 100 mg/day/
snail used in this study represents a dose lower than that 
required to eliminate the parasite. Furthermore, three 
treatments were carried out for five consecutive days 
with the goal being to expose the parasite periodically to 
PZQ to select or induce resistance. 
The results presented here demonstrate that adult 
worms of the LE-PZQ isolate were less susceptible to 
PZQ at doses of 200 and 400 mg/kg than the control 
strain (LE). Similar results were not observed between 
the LE and LE-PZQ isolates at a dose of 800 mg/kg. This 
dose was deemed to be enough to overcome the resist-
ance of the selected parasite. Interestingly, a dose of 
800 mg/kg in the susceptible strain (LE) shows the same 
results as with 400 mg/kg. However, when the dose is 
increased to 800 mg/kg, the drug kills around 88% of 
worms in the resistant isolate (LE-PZQ). In our in vitro 
experiments, adult worms obtained from mice treated 
with PZQ from the LE-PZQ isolate were less susceptible 
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to the drug. The LE-PZQ isolate has been maintained 
in our laboratory under the pressure of PZQ. Recent re-
sults confirm that this isolate remains less susceptible 
to PZQ (unpublished data). The complete mechanism of 
action of PZQ has not been clearly defined (Doenhoff 
et al. 2008), but it is well known that PZQ causes a se-
vere muscular contraction due to intense calcium influx 
(Pax et al. 1978), immediate tegumental lesions (Harnett 
& Kusel 1986), reduction of glutathione levels (Ribeiro 
et al. 1998) and interruption of the excretory activity 
of adult worms (Kusel et al. 2006, 2007, Oliveira et al. 
2006). After eight days of culture the adult worms of 
the LE strain showed typical alterations in morphology 
of susceptible parasites in contact with the drug includ-
ing intense contraction, reduced oviposition and tegu-
mental changes. Alternatively, PZQ (at 400 mg/Kg) was 
not able to cause the same alterations in the motility and 
oviposition in the worms from the LE-PZQ isolate. The 
results obtained in the in vitro experiment are significant 
because they allow us to observe the worm condition im-
mediately after contact with PZQ.
We found that the ED50 for the LE-PZQ isolate was 
significantly higher than for the LE strain in both experi-
ments. This parameter has been used to compare suscep-
tible and resistant worms. Cioli et al. (2004) estimated 
the ED50 from four susceptible and five putatively PZQ-
resistant isolates and suggested that the value of ED50 is 
useful for establishing and monitoring the drug suscep-
tibility/resistance profiles of the parasite strain. Further, 
they observed that the ED50 value was three times higher 
in the resistant isolates when compared with the suscep-
tible ones. Our results demonstrate that the ED50 of the 
LE-PZQ isolate was 5.3 times higher in comparison with 
the ED50 for the LE strain (susceptible). Both Fallon et al. 
(1996) and Bennett et al. (1997) suggested that the ED50 
for resistant isolates should be at least five times higher 
than that for those isolates susceptible to the drug. For 
Bennett et al. (1997), a three-to-five times higher dose is 
sufficient to differentiate between susceptible and resist-
ance strains.
According to Fallon et al. (1996), induction of resist-
ance performed in the laboratory using successive pas-
sages and treatments in mice are time-consuming and 
use dissimilar methodologies, thus rendering a difficult 
comparison of the analysis of the data. 
The study by Fallon and Doenhoff (1994) aimed at 
selecting PZQ resistant S. mansoni isolates was carried 
out with several passages of using the entire life cycle in 
mice and snails, with the infected mice being submitted 
to treatments with increasing doses of PZQ. This model 
for selection of resistant S. mansoni lineage is complex 
and time-consuming, but is able to select parasites at 
the adult worm phase. In our experimental studies, the 
chemotherapeutic pressure occurs on a higher number 
of parasites (thousands of cercariae and sporocysts) in 
the snail intermediate host. Thus, the selection of re-
sistant strains in the laboratory using S. mansoni at the 
intramolluscan phase seems to be more useful and this 
approach may be very important in studies concerning 
the development of novel antischistosomal drugs, as well 
as in those aimed at gaining a better understanding of 
the mechanisms related to resistance. These experiments 
must be repeated with other isolates. 
In conclusion, the use of the snail as an experimental 
model for development of resistance in S. mansoni is an 
effective, fast, simple and cheap method.
Fig. 2: adult worms of LE (susceptible) and LE-praziquantel (PZQ) (submitted to treatment with PZQ at the intramolluscan phase) derived from 
mice treated with 400 mg/kg PZQ and control, cultured for eight days. A: adult worm of the LE strain derived from mice treated with 400 mg/kg 
PZQ, exhibiting intense muscular contraction; B: adult worm of the LE-PZQ isolate derived from mice treated with 400 mg/kg PZQ, absence of 
muscular contraction; C: dead eggs laid by worms of the LE strain treated with 400 mg/kg; D: large number of eggs in all stages laid by worms 
of the strain LE-PZQ treated with 400 mg/kg; E: worms of the LE; F: LE-PZQ isolates derived from untreated mice (control), both have the same 
morphology after an eight-day-culture. Bars = 250 µm (A, B, D-F) and 100 µm (C).
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